Your browser doesn't support javascript.
loading
Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease.
Caillard, Pauline; Vigneau, Cécile; Halimi, Jean-Michel; Hazzan, Marc; Thervet, Eric; Heitz, Morgane; Juillard, Laurent; Audard, Vincent; Rabant, Marion; Hertig, Alexandre; Subra, Jean-François; Vuiblet, Vincent; Guerrot, Dominique; Tamain, Mathilde; Essig, Marie; Lobbedez, Thierry; Quemeneur, Thomas; Legendre, Mathieu; Ganea, Alexandre; Peraldi, Marie-Noëlle; Vrtovsnik, François; Daroux, Maïté; Makdassi, Raïfah; Choukroun, Gabriel; Titeca-Beauport, Dimitri.
Afiliação
  • Caillard P; Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France.
  • Vigneau C; Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires (MP3CV) laboratory, Centre de Recherche en Santé (CURS), Amiens, France.
  • Halimi JM; Rennes University Hospital, Inserm, Ecole des hautes études en santé publique (EHESP), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
  • Hazzan M; Department of Nephrology, Tours University Hospital and EA4245, University of Tours, Tours, France.
  • Thervet E; Nephrology Department, Lille University Hospital, University of Lille, UMR 995, Lille, France.
  • Heitz M; Department of Nephrology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris and INSERM UMRS970, Boulogne-Billancourt, France.
  • Juillard L; Department of Nephrology and Dialysis, Annecy Genevois Hospital, Pringy, France.
  • Audard V; Department of Nephrology, Edouard Herriot Hospital, Hospices Civils de Lyon, Carmen INSERM 1060 and Univ Lyon, Lyon, France.
  • Rabant M; Department of Nephrology and Renal Transplantation, Reference Center-Idiopathic Nephrotic Syndrome, Henri-Mondor Hospital/Albert-Chenevier, Assistance Publique-Hôpitaux de Paris (AP-HP) Créteil, INSERMU955, Paris Est Créteil University, Créteil, France.
  • Hertig A; Pathology Department, Necker University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Centre-Université de Paris, Paris, France.
  • Subra JF; Department of Nephrology, Dialysis and Transplantation, Foch Hospital, Paris-Saclay University, Suresnes, France.
  • Vuiblet V; Department of Nephrology, Dialysis and Transplantation, University Hospital, Angers and Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), INSERM, Nantes University, Angers University, Angers, France.
  • Guerrot D; Department of Nephrology and Renal Transplantation, Reims University Hospital, Reims, France.
  • Tamain M; Department of Nephrology, Rouen University Hospital, Rouen and INSERM, U1096 Rouen, France.
  • Essig M; Department of Nephrology and Dialysis, Vichy Hospital, Vichy, France.
  • Lobbedez T; Department of Nephrology, Dialysis, and Renal Transplantation, Ambroise-Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Boulogne-Billancourt, France.
  • Quemeneur T; Department of Nephrology, Caen University Hospital, Caen, France and the French Registry of Peritoneal Dialysis, Langue Française, Pontoise, France.
  • Legendre M; Department of Nephrology and Internal Medicine, Valenciennes General Hospital, Valenciennes, France.
  • Ganea A; Department of Nephrology, Dialysis and Renal Transplantation, University Hospital, Dijon, France.
  • Peraldi MN; Department of Nephrology, Orleans Hospital, Orleans, France.
  • Vrtovsnik F; Department of Nephrology, Dialysis and Renal Transplantation, Necker University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Centre-Université de Paris, Paris, France.
  • Daroux M; Nephrology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France. Faculty of Medicine, Paris Diderot University, Sorbonne Paris Cité, Paris, France.
  • Makdassi R; Department of Nephrology, Duchenne Hospital, Boulogne-Sur-Mer, France.
  • Choukroun G; Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France.
  • Titeca-Beauport D; Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France.
Front Immunol ; 14: 1190394, 2023.
Article em En | MEDLINE | ID: mdl-37475859
Background and objectives: Activation of the complement system is involved in the pathogenesis of anti-glomerular basement membrane (anti-GBM) disease. Glomerular deposits of complement 3 (C3) are often detected on kidney biopsies. The primary objective of this study was to analyze the prognostic value of the serum C3 level and the presence of C3 glomerular deposits in patients with anti-GBM disease. Methods: We conducted a retrospective cohort study of 150 single-positive patients with anti-GBM disease diagnosed between 1997 and 2017. Patients were categorized according to the serum C3 level (forming a low C3 (C3<1.23 g/L) and a high C3 (C3≥1.23 g/L) groups) and positivity for C3 glomerular staining (forming the C3+ and C3- groups). The main outcomes were kidney survival and patient survival. Results: Of the 150 patients included, 89 (65%) were men. The median [interquartile range (IQR)] age was 45 [26-64]. At diagnosis, kidney involvement was characterized by a median [IQR] peak serum creatinine (SCr) level of 578 [298-977] µmol/L, and 106 (71%) patients required dialysis. Patients in the low C3 group (72 patients) had more severe kidney disease at presentation, as characterized by higher prevalences of oligoanuria, peak SCr ≥500 µmol/L (69%, vs. 53% in the high C3 group; p=0.03), nephrotic syndrome (42%, vs. 24%, respectively; p=0.02) and fibrous forms on the kidney biopsy (21%, vs. 8%, respectively; p=0.04). Similarly, we observed a negative association between the presence of C3 glomerular deposits (in 52 (41%) patients) and the prevalence of cellular forms (83%, vs. 58% in the C3- group; p=0.003) and acute tubulo-interstitial lesions (60%, vs. 36% in the C3- group; p=0.007). When considering patients not on dialysis at diagnosis, the kidney survival rate at 12 months was poorer in the C3+ group (50% [25-76], vs. 91% [78-100] in the C3- group; p=0.01), with a hazard ratio [95% confidence interval] of 5.71 [1.13-28.85] (p=0.04, after adjusting for SCr). Conclusion: In patients with anti-GBM disease, a low serum C3 level and the presence of C3 glomerular deposits were associated with more severe disease and histological kidney involvement at diagnosis. In patients not on dialysis at diagnosis, the presence of C3 deposits was associated with worse kidney survival.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Antimembrana Basal Glomerular Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Antimembrana Basal Glomerular Idioma: En Ano de publicação: 2023 Tipo de documento: Article